Replies to post #180942 on Biotech Values

[oc631]

I suspect further investigation into all FDA approved SERM class compounds would take priority over TKM-Ebola. Granted it doesn't have to be one or the other.



http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955358/




Investing is emotion-based and few issues incite a larger emotional response than the threat of a pandemic. TKMR seems to be getting all the Ebola press and the company should benefit from greater-fool theory this week. Biotech investors know the challenges of RNAi delivery and that LNP isn't the missing link.



http://www.cbc.ca/news/health/nancy-writebol-u-s-missionary-didn-t-get-tkm-ebola-drug-tekmira-says-1.2726740